Apixaban: A review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation

Drugs

Volumn 73, Issue 8, 2013, Pages 825-843

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; DABIGATRAN ETEXILATE; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; AREA UNDER THE CURVE; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; THROMBOSIS PREVENTION; VEIN THROMBOSIS;

ASPIRIN; ATRIAL FIBRILLATION; EMBOLISM; FIBRINOLYTIC AGENTS; HUMANS; PYRAZOLES; PYRIDONES; STROKE; WARFARIN;

EID: 84878903500     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0063-x     Document Type: Review

References (88)

1. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719-47.
2. Deedwania P, Huang GW. Role of emerging antithrombotic therapy in prevention of cardioembolic complications in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2011;11(4):265-75.
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-67.
4. Deeks ED. Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery. Drugs. 2012;72(9):1271-91.
5. Lu G, Deguzman FR, Karbarz MJ, et al. Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote, PRT064445) [abstract no. 3715]. Eur Heart J. 2011;32(Suppl. 1):640-1.
6. Wong P, Watson C, Knabb R, et al. The combination of apixaban, a direct Xa inhibitor, with heparin or enoxaparin in rabbits elicits additive antithrombotic effects, with low bleeding [abstract no. 933]. Eur Heart J. 2008;29(Suppl. 1):133-4.
7. Alexander JH, Lopes R, McMurray J, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in patients taking concomitant aspirin [abstract no. 1192-600]. J Am Coll Cardiol. 2012;59(13 Suppl.):E1697.
8. Hollenbach SJ, Lu G, Tan S, et al. PRT064445 but not recombinant FVIIa reverses rivaroxaban induced anticoagulation as measured by reduction in blood loss in a rabbit liver laceration model [abstract no. 3414]. 54th American Society of Haematology annual meeting and exposition; 8-11 Dec 2012; Atlanta (GA).
9. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(5):1263-71.
10. Pinto DJ, Orwat MJ, Koch S, et al. Discovery of 1-(4-methoxyphenyl)-7- oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007;50(22):5339-56.
11. Wong PC, Pinto DJP, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478-92.
12. Luettgen JM, Knabb RM, He K, et al. Apixaban inhibition of factor Xa: microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J Enzyme Inhib Med Chem. 2011;26(4):514-26.
13. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1-22.
14. Jiang X, Crain EJ, Luettgen JM, et al. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost. 2009;101(4):780-2.
15. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6(5):820-9.
16. Becker RC, Alexander JH, Newby LK, et al. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010;104(5):976-83.
17. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation: the ARISTOTLE-J study. Circ J. 2011;75(8):1852-9.
18. Bristol-Myers Squibb Company. Eliquis (apixaban) tablets for oral use: US prescribing information; 2012. http://packageinserts.bms.com/pi/pi-eliquis.pdf (Accessed 30 Jan 2013).
19. Frost C, Wang J, Nepal S, et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):476-87.
20. Frost C, Nepal S, Wang J, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013. doi: 10.1111/bcp.12106.
21. European Medicines Agency. Eliquis (apixaban) film-coated tablets: EU summary of product characteristics; 2012. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/002148/WC500107728.pdf (Accessed 30 Jan 2013).
22. Barrett YC, Wang J, Knabb R, et al. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thromb Haemost. 2011;105(1):181-9.
23. Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost. 2010;104(2):302-10.
24. Schumacher WA, Bostwick JS, Stewart AB, et al. Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis. J Cardiovasc Pharmacol. 2010;55(6):609-16.
25. Wong PC, Crain EJ, Watson CA, et al. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost. 2009;7(8):1313-20.
26. Wong PC, Watson CA, Crain EJ. Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. J Thromb Haemost. 2008;6(10):1736-41.
27. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699-708.
28. Frost CE, Yu Z, Wang J, et al. Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment [abstract no. PI-84]. Clin Pharmacol Ther. 2009;85(Suppl. 1):S34.
29. Wang X, Tirucherai G, Pannacciulli N, et al. Effect of activated charcoal on the pharmacokinetics of apixaban in healthy subjects [abstract no. PI-90]. Clin Pharmacol Ther. 2012;91(Suppl. 1):S41.
30. Frost CE, Nepal S, Barrett Y. Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban [abstract no. PP-MO-407]. J Thromb Haemost. 2009;7(Suppl. 2):455.
31. Wang X, Tirucherai G, Ehlgen A, et al. Apixaban pharmacokinetics in subjects with end-stage renal disease on hemodialysis [abstract no. 1391147]. Clin Pharmacol Drug Dev. 2012;1(4):187.
32. Chang M, Shenker A, Wang J, et al. Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment [abstract no. 1381212]. Clin Pharmacol Drug Dev. 2012;1(4):185-6.
33. Wang L, Zhang D, Raghavan N, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448-58.
34. 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009;37(8):1738-48.
35. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74-81.
36. Zhang D, He K, Herbst JJ, et al. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013;41(4):827-35.
37. Zhang D, Frost CE, He K, et al. Investigating the enteroenteric recirculation of apixaban, a factor xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats. Drug Metab Dispos. 2013;41(4):906-15.
38. Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013. doi: 10.1111/bcp.12114.
39. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
40. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17.
41. Wallentin L, Lopes RD, Hanna M, et al. ARISTOTLE: efficacy and safety of apixaban compared to warfarin at different levels of INR control for stroke prevention in 18,202 patients with atrial fibrillation in the ARISTOTLE trial [abstract plus slide presentation]. European Society of Cardiology Congress 2011; 27-31 Aug 2011; Paris.
42. Granger CB, Alexander JH, Hanna M, et al. Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial [abstract no. 4045]. Eur Heart J. 2012;33 Suppl:685-6.
43. Garcia DA, Alexander JH, Lopes RD, et al. Apixaban versus warfarin in patients with atrial fibrillation in relation to prior warfarin use: insights from the ARISTOTLE trial [abstract no. 14771]. Circulation. 2012;126(21 Suppl.).
44. Bahit MC, Lopes RD, Hohnloser S, et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial [abstract no. 13026]. Circulation. 2012;126(21 Suppl.).
45. Wallentin LC, Christersson C, Siegbahn A, et al. NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin [abstract no. P551]. Eur Heart J. 2012;33(Suppl. 1):51.
46. Wallentin LC, Christersson C, Siegbahn A, et al. High sensitivity troponin-T for risk stratification in atrial fibrillation during treatment with apixaban or warfarin [abstract no. P558]. Eur Heart J. 2012;33(Suppl. 1):53.
47. Flaker G, Lopes R, Al-Khatib S, et al. Apixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation: results from the ARISTOTLE Trial [abstract no. 4048]. Eur Heart J. 2012;33(Suppl. 1):686.
48. Halvorsen S, Wallentin L, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation [abstract no. 914-4]. J Am Coll Cardiol. 2013;61(10 Suppl.):E315 plus slide presentation presented at the 62nd Annual Scientific Session and Exposition of the American College of Cardiology; 9-11 Mar 2013; San Francisco (CA).
49. Flaker GC, Hohnloser S, Wojdyla D, et al. Apixaban is efficacious and safe in patients with atrial fibrillation using concomitant amiodarone: an analysis from the ARISTOTLE trial [abstract no. 914-6]. J Am Coll Cardiol. 2013;61(10 Suppl.):E317 plus slide presentation presented at the 62nd Annual Scientific Session and Exposition of the American College of Cardiology; 9-11 Mar 2013; San Francisco (CA).
50. McMurray JJV. Apixaban vs warfarin in patients with atrial fibrillation: outcomes according to left ventricular systolic function and heart failure status in ARISTOTLE [slide presentation]. European Society of Cardiology Heart Failure Congress 2012; 19-22 May 2012; Belgrade.
51. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11(6):503-11.
52. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-30.
53. Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012;380(9855):1749-58.
54. Al-Khatib SM, Thomas L, Wallentin L, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J. 2013. doi: 10.1093/eurheartj/eht135.
55. Hohnloser S, Yusuf S, Eikelboom J, et al. Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial [abstract no. 3904]. Eur Heart J. 2011;32(Suppl. 1):671.
56. Eikelboom J, Synhorst D, Wright R, et al. Efficacy and safety of apixaban compared with aspirin in patients with atrial fibrillation who previously used and discontinued warfarin therapy: a secondary analysis of the AVERROES trial [abstract no. P2631]. Eur Heart J. 2011;32(Suppl. 1):465.
57. Diener H-C, Eikelboom J, Connolly SJ, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012;11(3):225-31.
58. Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012;21(6):429-35.
59. 2-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. Circ Arrhythm Electrophysiol. 2013;6(1):31-8.
60. Siegbahn A, Christersson C, Schollin M, et al. Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding: an ARISTOTLE substudy [abstract no. P553]. Eur Heart J. 2012;33(Suppl. 1):51.
61. Flaker GC, Eikelboom JW, Shestakovska O, et al. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial. Stroke. 2012;43(12):3291-7.
62. Lee S, Mullin R, Blazawski J, et al. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PLoS ONE. 2012;7(10):e47473.
63. Kamel H, Easton JD, Johnston SC, et al. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology. 2012;79(14):1428-34.
64. Lee S, Anglade MW, Meng J, et al. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin. Circ Cardiovasc Qual Outcomes. 2012;5(4):472-9.
65. Cowper PA, Pan W, Anstrom K, et al. Apixaban reduces hospitalization in patients with atrial fibrillation: an analysis of the effect of apixaban therapy on resource use in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial [abstract no. 1245-108]. J Am Coll Cardiol. 2013;61(10 Suppl.):E1576 plus poster presented at the 62nd Annual Scientific Session and Exposition of the American College of Cardiology; 9-11 Mar 2013; San Francisco (CA).
66. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638-45.
67. 2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012;107(6):1172-9.
68. Vassiliou VS, Flynn PD. Apixaban in atrial fibrillation: does predicted risk matter? Lancet. 2012;380(9855):1718-20.
69. Cucchiara BL, Kasner SE. Apixaban in atrial fibrillation: from bleeding cows to 21st century medicinal chemistry. Stroke. 2011;42(8):2376-8.
70. Nedeltchev K. Critique of apixaban versus warfarin in patients with atrial fibrillation. Stroke. 2012;43(3):922-3.
71. Escolar G, Arellano-Rodrigo E, Reverter CJ, et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood [abstract]. Circulation. 2012;126(4):521.
72. Portola Pharmaceuticals. Phase 2 healthy volunteer study to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests [ClinicalTrials.gov identifier NCT01758432]. US National Institutes of Health, ClinicalTrials.gov [online]; 2012. http://www. clinicaltrials.gov/ct2/show/NCT01758432 (Accessed 29 Jan 2013).
73. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.
74. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51.
75. Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa® (dabigatran etexilate mesylate) capsules: US prescribing information; 2012. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/022512s016lbl.pdf (Accessed 7 Feb 2013).
76. Steffel J, Hindricks G. Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis. Eur Heart J. 2012;33(22):2766-8.
77. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72.
78. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366(9):864-6.
79. European Medicines Agency. Pradaxa (dabigatran) hard capsules: EU summary of product characteristics; 2013. http://www.emea.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000829/WC500041059.pdf (Accessed 12 Feb 2013).
80. European Medicines Agency. Xarelto (rivaoxaban) film-coated tablets: EU summary of product characteristics; 2013. http://www.emea.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000944/WC500057108.pdf (Accessed 12 Feb 2013).
81. Janssen Pharmaceuticals Inc. Xarelto (rivaroxaban) tablets: US prescribing information; 2012. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2012/022406s001s002s003lbl.pdf (Accessed 7 Feb 2013).
82. Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med. 2011;365(11):1052-4.
83. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost. 2012;108(3):476-84.
84. Lip GY, Larsen TB, Skjoth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60(8):738-46.
85. Marx S, Diener HC, Harenberg J, et al. Network meta-analysis of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation [abstract no. P4695]. Eur Heart J. 2012;33(Suppl. 1):815.
86. Rasmussen LH, Larsen TB, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ. 2012;345:e7097.
87. Pisters R, Nieuwlaat R, Lane DA, et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation: a modelling analysis from the Euro Heart Survey. Thromb Haemost. 2013;109(2):328-36.
88. Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost. 2012;107(3):584-9.